1. Home
  2. TRDA vs HBCP Comparison

TRDA vs HBCP Comparison

Compare TRDA & HBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$12.65

Market Cap

500.4M

Sector

Health Care

ML Signal

HOLD

Logo Home Bancorp Inc.

HBCP

Home Bancorp Inc.

HOLD

Current Price

$62.32

Market Cap

453.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
HBCP
Founded
2016
1908
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
500.4M
453.4M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
TRDA
HBCP
Price
$12.65
$62.32
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$21.00
$65.50
AVG Volume (30 Days)
144.6K
135.0K
Earning Date
05-08-2026
04-20-2026
Dividend Yield
N/A
2.00%
EPS Growth
N/A
29.01
EPS
N/A
5.87
Revenue
$25,421,000.00
N/A
Revenue This Year
$39.97
N/A
Revenue Next Year
$50.80
$3.97
P/E Ratio
N/A
$10.57
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$47.96
52 Week High
$14.49
$65.95

Technical Indicators

Market Signals
Indicator
TRDA
HBCP
Relative Strength Index (RSI) 46.56 52.76
Support Level $10.84 $56.27
Resistance Level $12.93 $65.00
Average True Range (ATR) 0.58 1.75
MACD -0.19 -0.26
Stochastic Oscillator 23.92 29.35

Price Performance

Historical Comparison
TRDA
HBCP

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About HBCP Home Bancorp Inc.

Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.

Share on Social Networks: